BACKGROUND: IgG4-related disease (IgG4-RD) is a systemic condition of unknown cause characterized by highly fibrotic lesions with dense lymphoplasmacytic infiltrates. CD4(+) T cells constitute the major inflammatory cell population in IgG4-RD lesions. OBJECTIVE: We used an unbiased approach to characterize CD4(+) T-cell subsets in patients with IgG4-RD based on their clonal expansion and ability to infiltrate affected tissue sites. METHODS: We used flow cytometry to identify CD4(+) effector/memory T cells in a cohort of 101 patients with IgG4-RD. These expanded cells were characterized by means of gene expression analysis and flow cytometry. Next-generation sequencing of the T-cell receptor β chain gene was performed on CD4(+)SLAMF7(+) cytotoxic T lymphocytes (CTLs) and CD4(+)GATA3(+) TH2 cells in a subset of patients to identify their clonality. Tissue infiltration by specific T cells was examined by using quantitative multicolor imaging. RESULTS: CD4(+) effector/memory T cells with a cytolytic phenotype were expanded in patients with IgG4-RD. Next-generation sequencing revealed prominent clonal expansions of these CD4(+) CTLs but not CD4(+)GATA3(+) memory TH2 cells in patients with IgG4-RD. The dominant T cells infiltrating a range of inflamed IgG4-RD tissue sites were clonally expanded CD4(+) CTLs that expressed SLAMF7, granzyme A, IL-1β, and TGF-β1. Clinical remission induced by rituximab-mediated B-cell depletion was associated with a reduction in numbers of disease-associated CD4(+) CTLs. CONCLUSIONS: IgG4-RD is prominently linked to clonally expanded IL-1β- and TGF-β1-secreting CD4(+) CTLs in both peripheral blood and inflammatory tissue lesions. These active, terminally differentiated, cytokine-secreting effector CD4(+) T cells are now linked to a human disease characterized by chronic inflammation and fibrosis.
BACKGROUND: IgG4-related disease (IgG4-RD) is a systemic condition of unknown cause characterized by highly fibrotic lesions with dense lymphoplasmacytic infiltrates. CD4(+) T cells constitute the major inflammatory cell population in IgG4-RD lesions. OBJECTIVE: We used an unbiased approach to characterize CD4(+) T-cell subsets in patients with IgG4-RD based on their clonal expansion and ability to infiltrate affected tissue sites. METHODS: We used flow cytometry to identify CD4(+) effector/memory T cells in a cohort of 101 patients with IgG4-RD. These expanded cells were characterized by means of gene expression analysis and flow cytometry. Next-generation sequencing of the T-cell receptor β chain gene was performed on CD4(+)SLAMF7(+) cytotoxic T lymphocytes (CTLs) and CD4(+)GATA3(+) TH2 cells in a subset of patients to identify their clonality. Tissue infiltration by specific T cells was examined by using quantitative multicolor imaging. RESULTS:CD4(+) effector/memory T cells with a cytolytic phenotype were expanded in patients with IgG4-RD. Next-generation sequencing revealed prominent clonal expansions of these CD4(+) CTLs but not CD4(+)GATA3(+) memory TH2 cells in patients with IgG4-RD. The dominant T cells infiltrating a range of inflamed IgG4-RD tissue sites were clonally expanded CD4(+) CTLs that expressed SLAMF7, granzyme A, IL-1β, and TGF-β1. Clinical remission induced by rituximab-mediated B-cell depletion was associated with a reduction in numbers of disease-associated CD4(+) CTLs. CONCLUSIONS: IgG4-RD is prominently linked to clonally expanded IL-1β- and TGF-β1-secreting CD4(+) CTLs in both peripheral blood and inflammatory tissue lesions. These active, terminally differentiated, cytokine-secreting effector CD4(+) T cells are now linked to a human disease characterized by chronic inflammation and fibrosis.
Authors: Emanuel Della-Torre; Hamid Mattoo; Vinay S Mahajan; Vikram Deshpande; Donald Krause; Philip Song; Shiv Pillai; John H Stone Journal: Ann Rheum Dis Date: 2014-03-20 Impact factor: 19.103
Authors: Susan Johnson; Michael Eller; Jeffrey E Teigler; Sebastien M Maloveste; Bruce T Schultz; Damien Z Soghoian; Richard Lu; Alexander F Oster; Agnès-Laurence Chenine; Galit Alter; Ulf Dittmer; Mary Marovich; Merlin L Robb; Nelson L Michael; Diane Bolton; Hendrik Streeck Journal: J Virol Date: 2015-05-13 Impact factor: 5.103
Authors: S G Johansson; J O Hourihane; J Bousquet; C Bruijnzeel-Koomen; S Dreborg; T Haahtela; M L Kowalski; N Mygind; J Ring; P van Cauwenberge; M van Hage-Hamsten; B Wüthrich Journal: Allergy Date: 2001-09 Impact factor: 13.146
Authors: Hong-Lei Weng; Yan Liu; Jia-Lin Chen; Tong Huang; Li-Jun Xu; Patricio Godoy; Jun-Hua Hu; Cheng Zhou; Felix Stickel; Alexander Marx; Rainer M Bohle; Vincent Zimmer; Frank Lammert; Sebastian Mueller; Michelle Gigou; Didier Samuel; Peter R Mertens; Manfred V Singer; Helmut K Seitz; Steven Dooley Journal: Hepatology Date: 2009-07 Impact factor: 17.425
Authors: Hang Liu; Cory A Perugino; Musie Ghebremichael; Zachary S Wallace; Sydney B Montesi; John H Stone; Shiv Pillai Journal: Arthritis Rheumatol Date: 2020-02-10 Impact factor: 10.995
Authors: Cory A Perugino; Sultan B AlSalem; Hamid Mattoo; Emanuel Della-Torre; Vinay Mahajan; Gayathri Ganesh; Hugues Allard-Chamard; Zachary Wallace; Sydney B Montesi; Johannes Kreuzer; Wilhelm Haas; John H Stone; Shiv Pillai Journal: J Allergy Clin Immunol Date: 2018-05-29 Impact factor: 10.793
Authors: Katherine B Sulka; Klemen Strle; Jameson T Crowley; Robert B Lochhead; Robert Anthony; Allen C Steere Journal: Arthritis Rheumatol Date: 2018-09-24 Impact factor: 10.995